Insider · CIK 0001203602
Michael D Cannon
Files at MBRX (Moleculin Biotech, Inc.). First filing -, latest -.
In brief
Michael D Cannon files SEC Form 4 as director at MBRX (Moleculin Biotech, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michael D Cannon has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | MBRX Moleculin Biotech, Inc. | AGrant or award Stock Options (right to buy)derivative | +150,000 | - | - | 165,336 | Nov 14, 2025 |
| Nov 4, 2024 | MBRX Moleculin Biotech, Inc. | AGrant or award Stock option (right to buy)derivative | +10,000 | - | - | 15,336 | Nov 6, 2024 |
Questions about Michael D Cannon
Answered from the filings on this page, as of the latest one.
Is Michael D Cannon buying or selling?
Michael D Cannon has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michael D Cannon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael D Cannon has 0.
Where does Michael D Cannon file Form 4?
Michael D Cannon has filed Form 4 at MBRX (Moleculin Biotech, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.